Fig. 3From: High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysisForest plot of the subgroup analysis assessing the reduction in the migraine symptoms. We reported the mean reduction in HIT6, MIDAS, VAS scores and the mean reduction in migraine frequency (i.e. number of headache attacks per month) after 6 months of treatmentBack to article page